An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Summary

A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.

Timeline

Start

2024-11-05

Primary completion

2030-04-30

Completion

2030-04-30

Drugs

Indications